Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.50, which may not compare to the analyst estimate of $0.53. Revenue for the quarter came in at $121.7 million versus the consensus estimate of $120.16 million.

GUIDANCE:

Halozyme Therapeutics sees FY2021 EPS of $1.40-$1.55, which may not compare to the consensus of $1.70. Halozyme Therapeutics sees FY2021 revenue of $375-395 million, versus the consensus of $400.15 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.